Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Bought by Suvretta Capital Management LLC

Suvretta Capital Management LLC raised its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 422.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,829,053 shares of the biotechnology company’s stock after buying an additional 7,137,763 shares during the quarter. Benitec Biopharma comprises 2.6% of Suvretta Capital Management LLC’s investment portfolio, making the stock its 8th largest holding. Suvretta Capital Management LLC owned approximately 83.64% of Benitec Biopharma worth $81,139,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Benitec Biopharma by 53.0% during the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,884 shares during the last quarter. Acuta Capital Partners LLC acquired a new position in shares of Benitec Biopharma in the third quarter valued at $274,000. Simplify Asset Management Inc. acquired a new position in shares of Benitec Biopharma in the second quarter valued at $358,000. Janus Henderson Group PLC raised its stake in shares of Benitec Biopharma by 35.5% in the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 64,092 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Benitec Biopharma in the second quarter valued at $5,881,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BNTC shares. Guggenheim started coverage on Benitec Biopharma in a research note on Thursday, September 12th. They issued a “buy” rating and a $17.00 target price for the company. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Oppenheimer began coverage on Benitec Biopharma in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, JMP Securities upped their price target on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Monday, October 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $22.60.

Benitec Biopharma Trading Down 1.2 %

Shares of NASDAQ:BNTC opened at $9.73 on Friday. The business’s fifty day moving average price is $10.16 and its two-hundred day moving average price is $9.12. Benitec Biopharma Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $12.89.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.